Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Resource Allocation
Caspase 9
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents.
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Benzamides
Blast Crisis
Disease Progression
Female
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Kaplan-Meier Estimate
Leukemia, Myeloid, Chronic-Phase
Male
Middle Aged
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Young Adult
authors with profiles
Richard A. Larson